MedTrace Logo

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01954576 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-10-31

No results posted yet for this study

Summary

This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme. NovoTTF therapy uses a low intensity electric current to kill tumor cells. NovoTTF therapy may be effective treatment for brain cancer.

Conditions

Interventions

DEVICE

NovoTTF-100A

PROCEDURE

Quality-of-life assessment

GENETIC

Laboratory biomarker analysis

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • NovoCure Ltd.

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • David Tran, M.D., Ph.D. · University of Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-10
Primary Completion
2021-05-14
Completion
2021-05-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954576 on ClinicalTrials.gov